- Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non-small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasisWu, Yi-Long; Zhou, Qing; Wang, Jie; Yu, Yan; Xing, Ligang; Wang, Ying; Cheng, Ying; Pan, Yueyin; Fan, Yun; Shi, Jianhua; Zhang, Guojun; Cui, Jiuwei; Zhou, Jianying; Song, Yong; Zhuang, Wu; Ma, Zhiyong; Hu, Yanping; Li, Gaofeng; Dong, Xiaorong; Ahn, Myung-JuAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.被引 4
- Aumolertinib activity in patients with CNS metastases and EGFR-mutated NSCLC treated in the randomized double-blind phase III trial (AENEAS).Lu, Shun; Dong, Xiaorong; Jian, Hong; Chen, Jianhua; Chen, Gongyan; Sun, Yuping; Ji, Yinghua; Wang, Ziping; Shi, Jianhua; Lu, JunGuo; Chen, Shaoshui; Lv, Dongqing; Zhang, Guojun; Liu, Chunling; Li, Juan; Yu, Xinmin; Lin, Zhong; Yu, Zhuang; Wang, Zhehai; Cui, JiuweiAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
- High-dose aumolertinib in EGFR-mutant NSCLC patients with brain metastases: Primary data from ACHIEVEFan, Y.; Zhu, J.; He, J.; Zhou, R.; Chen, J.; Han, G.; Ren, B. Y.ESMO Asia Congress, Singapore, SINGAPORE, 2022-12-02 To 2022-12-04.
会议论文
Efficacy and safety of AZD3759 in previously untreated EGFR-mutant non-small cell lung cancer with central nervous system metastases in a multi-center, phase II umbrella trial (CTONG1702)
16阅读
